Cornelis F M Sier

List of Publications by Year
in descending order

118 papers	5,041 citations	76326 40 h-index	95266 68 g-index
120 all docs	120 docs citations	120 times ranked	7089 citing authors

#	Article	IF	Citations
1	Vitamin D in Head and Neck Cancer: a Systematic Review. Current Oncology Reports, 2021, 23, 5.	4.0	12
2	Cell-Based Tracers as Trojan Horses for Image-Guided Surgery. International Journal of Molecular Sciences, 2021, 22, 755.	4.1	9
3	Candidate Biomarkers for Specific Intraoperative Near-Infrared Imaging of Soft Tissue Sarcomas: A Systematic Review. Cancers, 2021, 13, 557.	3.7	10
4	CEA, EpCAM, Î±vÎ²6 and uPAR Expression in Rectal Cancer Patients with a Pathological Complete Response after Neoadjuvant Therapy. Diagnostics, 2021, 11, 516.	2.6	5
5	A multimodal molecular imaging approach targeting urokinase plasminogen activator receptor for the diagnosis, resectionÂand surveillance of urothelial cell carcinoma. European Journal of Cancer, 2021, 146, 11-20.	2.8	8
6	Endoglin/CD105-Based Imaging of Cancer and Cardiovascular Diseases: A Systematic Review. International Journal of Molecular Sciences, 2021, 22, 4804.	4.1	10
7	NIR Fluorescence Imaging of Colon Cancer With cRGD-ZW800-1â€"Response. Clinical Cancer Research, 2021, 27, 4938-4938.	7.0	0
8	Introducing Fluorescence-Guided Surgery for Pediatric Ewing, Osteo-, and Rhabdomyosarcomas: A Literature Review. Biomedicines, 2021, 9, 1388.	3.2	14
9	Side-by-Side Comparison of uPAR-Targeting Optical Imaging Antibodies and Antibody Fragments for Fluorescence-Guided Surgery of Solid Tumors. Molecular Imaging and Biology, 2021, , 1.	2.6	6
10	An Immunohistochemical Evaluation of Tumor-Associated Glycans and Mucins as Targets for Molecular Imaging of Pancreatic Ductal Adenocarcinoma. Cancers, 2021, 13, 5777.	3.7	3
11	Integrin Î±vÎ²6 as a Target for Tumor-Specific Imaging of Vulvar Squamous Cell Carcinoma and Adjacent Premalignant Lesions. Cancers, 2021, 13, 6006.	3.7	1
12	Overview and Future Perspectives on Tumor-Targeted Positron Emission Tomography and Fluorescence Imaging of Pancreatic Cancer in the Era of Neoadjuvant Therapy. Cancers, 2021, 13, 6088.	3.7	8
13	Molecular targets for diagnostic and intraoperative imaging of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX treatment. Scientific Reports, 2020, 10, 16211.	3.3	12
14	Glycan-Based Near-infrared Fluorescent (NIRF) Imaging of Gastrointestinal Tumors: a Preclinical Proof-of-Concept In Vivo Study. Molecular Imaging and Biology, 2020, 22, 1511-1522.	2.6	6
15	Anti-GD2-IRDye800CW as a targeted probe for fluorescence-guided surgery in neuroblastoma. Scientific Reports, 2020, 10, 17667.	3.3	20
16	Evaluation of EphB4 as Target for Image-Guided Surgery of Breast Cancer. Pharmaceuticals, 2020, 13, 172.	3.8	1
17	Small Molecules for Multi-Wavelength Near-Infrared Fluorescent Mapping of Regional and Sentinel Lymph Nodes in Colorectal Cancer Staging. Frontiers in Oncology, 2020, 10, 586112.	2.8	1
18	Welcome to Surgeries: A New Open Access Platform for Clinical and Experimental Research and Developments in All Fields of Surgery. Surgeries, 2020, 1, 1-1.	0.6	0

#	Article	IF	Citations
19	EGFR and Î±vÎ²6 as Promising Targets for Molecular Imaging of Cutaneous and Mucosal Squamous Cell Carcinoma of the Head and Neck Region. Cancers, 2020, 12, 1474.	3.7	17
20	Novel Molecular Targets for Tumor-Specific Imaging of Epithelial Ovarian Cancer Metastases. Cancers, 2020, 12, 1562.	3.7	9
21	Identifying Biomarkers in Lymph Node Metastases of Esophageal Adenocarcinoma for Tumor-Targeted Imaging. Molecular Diagnosis and Therapy, 2020, 24, 191-200.	3.8	8
22	Potential targets for tumor-specific imaging of vulvar squamous cell carcinoma: A systematic review of candidate biomarkers. Gynecologic Oncology, 2020, 156, 734-743.	1.4	6
23	Targeting Endoglin-Expressing Regulatory T Cells in the Tumor Microenvironment Enhances the Effect of PD1 Checkpoint Inhibitor Immunotherapy. Clinical Cancer Research, 2020, 26, 3831-3842.	7.0	28
24	Molecular imaging of the urokinase plasminogen activator receptor: opportunities beyond cancer. EJNMMI Research, 2020, 10, 87.	2.5	16
25	Targeting Glycans and Heavily Glycosylated Proteins for Tumor Imaging. Cancers, 2020, 12, 3870.	3.7	13
26	ITGA5 inhibition in pancreatic stellate cells attenuates desmoplasia and potentiates efficacy of chemotherapy in pancreatic cancer. Science Advances, 2019, 5, eaax2770.	10.3	81
27	A method for semi-automated image analysis of HLA class I tumour epithelium expression in rectal cancer. European Journal of Histochemistry, 2019, 63, .	1.5	2
28	Increased expression of cancer-associated fibroblast markers at the invasive front and its association with tumor-stroma ratio in colorectal cancer. BMC Cancer, 2019, 19, 284.	2.6	95
29	Fluorescence-guided tumor detection with a novel anti-EpCAM targeted antibody fragment: Preclinical validation. Surgical Oncology, 2019, 28, 1-8.	1.6	24
30	Abstract P6-01-01: Immunohistochemical staining andin vitroanalysis of HER2-positive breast cancer using trastuzumab and pertuzumab to develop an appropriate tracer in image-guided surgery. , 2019, , .		0
31	Abstract 291: Synergistic inhibition of cancer invasion and metastasis by combined anti-PD1-TRC105-mediated Endoglin targeting on cancer-associated fibroblasts and endothelial cells. , 2019, , .		0
32	EP952â€…Novel molecular target selection for tumour-specific imaging of metastases from epithelial ovarian cancer. , 2019, , .		0
33	Abstract 291: Synergistic inhibition of cancer invasion and metastasis by combined anti-PD1-TRC105-mediated Endoglin targeting on cancer-associated fibroblasts and endothelial cells. , 2019, , .		0
34	Fluorescenceâ€•and multispectral optoacoustic imaging for an optimized detection of deeply located tumors in an orthotopic mouse model of pancreatic carcinoma. International Journal of Cancer, 2018, 142, 2118-2129.	5.1	8
35	Introducing fluorescence guided surgery into orthopedic oncology: A systematic review of candidate protein targets for Ewing sarcoma. Journal of Surgical Oncology, 2018, 118, 906-914.	1.7	12
36	Endoglin Expression on Cancer-Associated Fibroblasts Regulates Invasion and Stimulates Colorectal Cancer Metastasis. Clinical Cancer Research, 2018, 24, 6331-6344.	7.0	138

#	Article	IF	Citations
37	Biomarker expression in rectal cancer tissue before and after neoadjuvant therapy. OncoTargets and Therapy, 2018, Volume 11, 1655-1664.	2.0	14
38	Preclinical uPAR-targeted multimodal imaging of locoregional oral cancer. Oral Oncology, 2017, 66, 1-8.	1.5	28
39	Endoglin as an Important Regulator of Colorectal Cancer Invasion and Metastasis. Gastroenterology, 2017, 152, S87.	1.3	0
40	Morphological and phenotypical features of ovarian metastases in breast cancer patients. BMC Cancer, 2017, 17, 206.	2.6	7
41	Prognostic Impact of Urokinase Plasminogen Activator Receptor Expression in Pancreatic Cancer: Malignant Versus Stromal Cells. Biomarker Insights, 2017, 12, 117727191771544.	2.5	16
42	In Search for Optimal Targets for Intraoperative Fluorescence Imaging of Peritoneal Metastasis From Colorectal Cancer. Biomarkers in Cancer, 2017, 9, 1179299X1772825.	3.6	14
43	Evaluation of EphA2 and EphB4 as Targets for Image-Guided Colorectal Cancer Surgery. International Journal of Molecular Sciences, 2017, 18, 307.	4.1	14
44	Real-time near-infrared fluorescence imaging using cRGD-ZW800-1 for intraoperative visualization of multiple cancer types. Oncotarget, 2017, 8, 21054-21066.	1.8	60
45	uPAR directed-imaging of head-and-neck cancer. Oncotarget, 2017, 8, 20519-20520.	1.8	6
46	Selection of optimal molecular targets for tumor-specific imaging in pancreatic ductal adenocarcinoma. Oncotarget, 2017, 8, 56816-56828.	1.8	32
47	EpCAM as multi-tumour target for near-infrared fluorescence guided surgery. BMC Cancer, 2016, 16, 884.	2.6	36
48	Identification of cell-surface markers for detecting breast cancer cells in ovarian tissue. Archives of Gynecology and Obstetrics, 2016, 294, 385-393.	1.7	6
49	Selecting Targets for Tumor Imaging: An Overview of Cancer-Associated Membrane Proteins. Biomarkers in Cancer, 2016, 8, BIC.S38542.	3.6	82
50	Selecting Tumor-Specific Molecular Targets in Pancreatic Adenocarcinoma: Paving the Way for Image-Guided Pancreatic Surgery. Molecular Imaging and Biology, 2016, 18, 807-819.	2.6	47
51	Endoglin targeting inhibits tumor angiogenesis and metastatic spread in breast cancer. Oncogene, 2016, 35, 4069-4079.	5.9	55
52	Preclinical evaluation of a novel <scp>CEA</scp>â€targeting nearâ€infrared fluorescent tracer delineating colorectal and pancreatic tumors. International Journal of Cancer, 2015, 137, 1910-1920.	5.1	55
53	Stromal Targets for Fluorescent-Guided Oncologic Surgery. Frontiers in Oncology, 2015, 5, 254.	2.8	18
54	uPAR-targeted multimodal tracer for pre- and intraoperative imaging in cancer surgery. Oncotarget, 2015, 6, 14260-14273.	1.8	42

#	Article	IF	Citations
55	Abstract 4130: Dual targeting of VEGF and endoglin inhibits tumor angiogenesis and metastatic spread. , 2015, , .		0
56	Interaction with colon cancer cells hyperactivates TGF-Î²2 signaling in cancer-associated fibroblasts. Oncogene, 2014, 33, 97-107.	5.9	216
57	Clinical prognostic value of combined analysis of Aldh1, Survivin, and EpCAM expression in colorectal cancer. British Journal of Cancer, 2014, 110, 2935-2944.	6.4	73
58	Expression of uPAR in tumor-associated stromal cells is associated with colorectal cancer patient prognosis: a TMA study. BMC Cancer, 2014, 14, 269.	2.6	33
59	Bone healing and Mannose-Binding Lectin. International Journal of Surgery, 2013, 11, 296-300.	2.7	13
60	Circulating bone morphogenetic protein levels and delayed fracture healing. International Orthopaedics, 2013, 37, 523-527.	1.9	45
61	Cytoplasmic Overexpression of HER2: A Key Factor in Colorectal Cancer. Clinical Medicine Insights: Oncology, 2013, 7, CMO.S10811.	1.3	62
62	Injury pattern, injury severity, and mortality in 33,495 hospital-admitted victims of motorized two-wheeled vehicle crashes in The Netherlands. Journal of Trauma, 2012, 72, 1363-1368.	2.3	32
63	MMP-2 and MMP-9 in normal mucosa are independently associated with outcome of colorectal cancer patients. British Journal of Cancer, 2012, 106, 1495-1498.	6.4	68
64	Reply to the letter to the editor: Could the use of bone morphogenetic proteins in fracture healing do more harm than good to our patients?. International Orthopaedics, 2012, 36, 685-685.	1.9	1
65	Single-nucleotide polymorphisms of matrix metalloproteinases and their inhibitors in gastrointestinal cancer. World Journal of Gastrointestinal Oncology, 2011, 3, 79.	2.0	22
66	Clinical Applications of the Urokinase Receptor (uPAR) for Cancer Patients. Current Pharmaceutical Design, 2011, 17, 1890-1910.	1.9	64
67	Implant removal associated complications in children with limb fractures due to trauma. European Journal of Trauma and Emergency Surgery, 2011, 37, 623-627.	1.7	25
68	Use and efficacy of bone morphogenetic proteins in fracture healing. International Orthopaedics, 2011, 35, 1271-1280.	1.9	215
69	Displaced midshaft fractures of the clavicle: non-operative treatment versus plate fixation (Sleutel-TRIAL). A multicentre randomised controlled trial. BMC Musculoskeletal Disorders, 2011, 12, 196.	1.9	28
70	Matrix Metalloproteinase-14 (MT1-MMP)â€“Mediated Endoglin Shedding Inhibits Tumor Angiogenesis. Cancer Research, 2010, 70, 4141-4150.	0.9	231
71	5-Aminosalicylic acid inhibits TGF-Î²1 signalling in colorectal cancer cells. Cancer Letters, 2010, 287, 82-90.	7.2	20
72	Clinical significance of stromal apoptosis in colorectal cancer. British Journal of Cancer, 2009, 101, 765-773.	6.4	15

#	Article	IF	Citations
73	Matrix metalloproteinases and their tissue inhibitors as prognostic indicators for diagnostic and surgical recurrence in CrohnÊ¼s disease. Inflammatory Bowel Diseases, 2009, 15, 84-92.	1.9	19
74	Active TGFâ€Î²1 correlates with myofibroblasts and malignancy in the colorectal adenomaâ€carcinoma sequence. Cancer Science, 2009, 100, 663-670.	3.9	42
75	Expression of endoglin (CD105) in cervical cancer. British Journal of Cancer, 2009, 100, 1617-1626.	6.4	38
76	MMP-2 geno-phenotype is prognostic for colorectal cancer survival, whereas MMP-9 is not. British Journal of Cancer, 2008, 98, 1820-1823.	6.4	43
77	VEGF release by MMP-9 mediated heparan sulphate cleavage induces colorectal cancer angiogenesis. European Journal of Cancer, 2008, 44, 1904-1913.	2.8	177
78	Tissue level, activation and cellular localisation of TGF-Î²1 and association with survival in gastric cancer patients. British Journal of Cancer, 2007, 97, 398-404.	6.4	80
79	Clinical evidence for a protective role of lipocalin-2 against MMP-9 autodegradation and the impact for gastric cancer. European Journal of Cancer, 2007, 43, 1869-1876.	2.8	128
80	Efficient degradation-aided selection of protease inhibitors by phage display. Biochemical and Biophysical Research Communications, 2007, 364, 549-555.	2.1	7
81	Endothelium specific matrilysin (MMP-7) expression in human cancers. Matrix Biology, 2007, 27, 267-71.	3.6	13
82	Increased mucosal matrix metalloproteinase-1, -2, -3 and -9 activity in patients with inflammatory bowel disease and the relation with Crohn's disease phenotype. Digestive and Liver Disease, 2007, 39, 733-739.	0.9	123
83	Determination of matrilysin activity in gastrointestinal neoplasia. European Journal of Clinical Investigation, 2007, 37, 598-599.	3.4	4
84	Eradication of Helicobacter pylori Infection Favourably Affects Altered Gastric Mucosal MMP-9 Levels. Helicobacter, 2007, 12, 498-504.	3.5	29
85	Clinical impact of MMP and TIMP gene polymorphisms in gastric cancer. British Journal of Cancer, 2006, 95, 744-751.	6.4	105
86	Matrix metalloproteinase-2 is a consistent prognostic factor in gastric cancer. British Journal of Cancer, 2006, 94, 1035-1040.	6.4	88
87	Cross-linking tumor cells with effector cells via CD55 with a bispecific mAb induces Î²-glucan-dependent CR3-dependent cellular cytotoxicity. European Journal of Immunology, 2006, 36, 977-984.	2.9	19
88	EMMPRIN-induced MMP-2 activation cascade in human cervical squamous cell carcinoma. International Journal of Cancer, 2006, 118, 2991-2998.	5.1	49
89	ID: 108 HIGH MMP-9/NGAL COMPLEX LEVELS IN GASTRIC CANCER TISSUE ARE ASSOCIATED WITH WORSE SURVIVAL. Journal of Thrombosis and Haemostasis, 2006, 4, 127-127.	3.8	0
90	ID: 110 MATRIX METALLOPROTEINASES AND THEIR INHIBITORS IN GASTRIC CANCER: CLINICAL APPLICATION OF GENES AND PROTEINS. Journal of Thrombosis and Haemostasis, 2006, 4, 128-128.	3.8	0

#	Article	IF	Citations
91	ID: 111 INFLIXIMAB INDUCES A GENOTYPE-DEPENDENT MUCOSA PROTECTIVE MATRIX METALLOPROTEINASE PHENOTYPE IN INFLAMMATORY BOWEL DISEASE. Journal of Thrombosis and Haemostasis, 2006, 4, 129-129.	3.8	30
92	Expression of matrix metalloproteinases-2 and -9 in intestinal tissue of patients with inflammatory bowel diseases. Digestive and Liver Disease, 2005, 37, 584-592.	0.9	116
93	Metabolism of tumour-derived urokinase receptor and receptor fragments in cancer patients and xenografted mice. Thrombosis and Haemostasis, 2004, 91, 403-411.	3.4	28
94	Beta-glucan enhanced killing of renal cell carcinoma micrometastases by monoclonal antibody G250 directed complement activation. International Journal of Cancer, 2004, 109, 900-908.	5.1	40
95	Urinary levels of urokinase-type plasminogen activator and its receptor in the detection of bladder carcinoma. Cancer, 2003, 98, 1995-1995.	4.1	3
96	PAI-1 inhibits urokinase-induced chemotaxis by internalizing the urokinase receptor. FEBS Letters, 2001, 505, 249-254.	2.8	63
97	Proteolysis of the urokinase-type plasminogen activator receptor by metalloproteinase-12: implication for angiogenesis in fibrin matrices. Blood, 2001, 97, 3123-3131.	1.4	100
98	Plasminogen activators in multiple sclerosis lesions: Implications for the inflammatory response and axonal damage. Brain, 2001, 124, 1978-1988.	7.6	114
99	Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood, 2000, 96, 4091-4095.	1.4	185
100	Shedding and cleavage of the urokinase receptor (uPAR): identification and characterisation of uPAR fragments in vitro and in vivo. FEBS Letters, 2000, 475, 52-56.	2.8	103
101	MMP-9 Activity in Urine from Patients with Various Tumors, as Measured by a Novel MMP Activity Assay Using Modified Urokinase as a Substrate. Annals of the New York Academy of Sciences, 1999, 878, 141-149.	3.8	20
102	Superoxide dismutases in relation to the overall survival of colorectal cancer patients. British Journal of Cancer, 1998, 78, 1051-1057.	6.4	84
103	High performance density gradient electrophoresis of subcellular organelles, protein complexes and proteins. Electrophoresis, 1998, 19, 1171-1178.	2.4	9
104	Contribution of plasminogen activators and their inhibitors to the survival prognosis of patients with Dukes' stage B and C colorectal cancer. British Journal of Cancer, 1997, 75, 1793-1801.	6.4	41
105	Gastric mucosal plasminogen activators inHelicobacter pylori infection. Digestive Diseases and Sciences, 1996, 41, 1577-1582.	2.3	13
106	The effect of treatment of Helicobacter pylori infection on gastric mucosal plasminogen activators. Fibrinolysis, 1996, 10, 85-89.	0.5	5
107	Prognostic value of the plasminogen activation system in patients with gastric carcinoma. Cancer, 1996, 77, 1035-1043.	4.1	53
108	Tissue levels of matrix metalloproteinases MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. British Journal of Cancer, 1996, 74, 413-417.	6.4	268

#	Article	IF	Citations
109	Plasminogen activators and inhibitor type 1 in neoplastic colonic tissue from patients with familial adenomatous polyposis. British Journal of Cancer, 1995, 71, 393-396.	6.4	20
110	Prognostic value of plasminogen activators and their inhibitors in colorectal cancer. European Journal of Cancer, 1995, 31, 1105-1109.	2.8	44
111	Tetranectin expression in human colonic neoplasia. Histopathology, 1994, 25, 463-467.	2.9	18
112	Glutathione S-transferases in liver metastases of colorectal cancer. A comparison with normal liver and primary carcinomas. Carcinogenesis, 1994, 15, 2149-2153.	2.8	19
113	Urokinase receptor and colorectal cancer survival. Lancet, The, 1994, 344, 401-402.	13.7	174
114	Inactive urokinase and increased levels of its inhibitor type 1 in colorectal cancer liver metastasis. Gastroenterology, 1994, 107, 1449-1456.	1.3	69
115	Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach.. Gut, 1993, 34, 80-85.	12.1	59
116	Association of aneuploidy in index adenomas with metachronous colorectal adenoma development and a comparison. Cancer, 1992, 70, 2035-2043.	4.1	10
117	Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Gastroenterology, 1991, 101, 1522-1528.	1.3	72
118	Immunolocalization of urokinase-type plasminogen activator in adenomas and carcinomas of the colorectum. Histopathology, 1991, 19, 231-238.	2.9	39